Next-IO™ Anti-PSMA × CD3 Therapeutic Bispecific Antibody Program

About This Program

This program aims to develop anti-PSMA × CD3 therapeutic Bispecific Antibody for immuno-oncology.

Rationale when developing the program:

• Currently, prostate cancer (CRPC) is still considered as incurable and new treatments are required.
• Prostate-specific membrane antigen (PSMA) is expressed on the surface of prostate cancer cells, and expression level increases as the disease progression.
• Some known treatments of PSMA - such as radiolabeled antibodies, chimeric antigen receptor T cells (CAR-Ts) have shown promising efficacy.
• Emerging clinical data reveals that T cell engagers can direct T cells to specific tumor cells, resulting in increased potency or tumor selectivity.

Given the above, we propose a novel combination - PSMA / CD3 therapeutic BiTE, which we believe will provide insights in next-generation cancer treatment.

PSMA

PSMA is a highly prostate-restricted membrane protein that expressed in almost all types of prostate cancer, which makes PSMA a potential target in local and metastatic prostate cancer. In particular, PSMA-targeting agents can be radiolabeled with diagnostic and/or therapeutic radionuclides. The end-products hold great clinical potential for the personalized management of metastatic prostate cancer. During the past few years, PSMA-specific tumor-targeting cell therapeutics are evolved so much and give a new outlook to use in the clinical settings.

Fig.1 PSMA: A versatile tool for prostate cancer therapy.

PSMA × CD3 in Cancer Studies

Here are some published data about PSMA × CD3 working as a potential target for cancer immunotherapy.

• PSMA Bispecific Antibody (BiJ591, AMG 212/BAY2010112, and MOR209/ES414) displays strong anti-tumor activity in CRPC.

Ongoing Clinical Trials

• According to the report, several anti-PSMA × CD3 therapeutic Bispecific Antibody is being evaluated in clinical studies. However, efficacy, safety, and combination strategies still need to be optimized.
• With all the supporting data, we believe PSMA × CD3 Bispecific Antibody is a compelling combination to research in cancer immunotherapy. In an effort to optimally leverage PSMA-mediated immune response, our next generation of PSMA targeting treatment attempts to explore combination therapy trials by involving other immunomodulatory agents.

Program Planning and Management

Creative Biolabs has extensive knowledge to develop end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-PSMA × CD3 therapeutic Bispecific Antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.

Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners to advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.

References

• Palamiuc L., et al. PSMA brings new flavors to PI3K signaling: A role for glutamate in prostate cancer[J]. The Journal of Experimental Medicine, 2017: jem.20172050.
• Leconet W., et al. Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation[J]. Large Molecule Therapeutics, 2018 10.1158/1535-7.
• Friedrich M., et al. Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific Bispecific Antibody Antibody Cross-Reactive with Non-Human Primate Antigens[J]. Molecular Cancer Therapeutics, 2012, 11(12): 2664-2673.
• Hernandez-Hoyos G., et al. MOR209/ES414, A Novel Bispecific Antibody Targeting PSMA For The Treatment of Metastatic Castration-Resistant Prostate Cancer[J]. Molecular Cancer Therapeutics, 2016: 1535-7163.MCT-15-0242.

For Research Use Only | Not For Clinical Use